<DOC>
	<DOC>NCT01491620</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).</brief_summary>
	<brief_title>Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Pigmentation Disorders</mesh_term>
	<mesh_term>Photosensitivity Disorders</mesh_term>
	<criteria>Fitzpatrick Skin Type I III Clinical diagnosis of poikiloderma of Civatte affecting the neck and/or chest Willing to refrain from using topical corticosteroids, retinoids and bleaching agents on the treated area Agree not to undergo any other procedure for the treatment of poikiloderma of Civatte during the study Willing and able to read, understand and sign the Informed Consent Form Willing and able to adhere to the treatment and followup schedule and posttreatment care instructions Any laser treatment on neck and/or chest within 12 months Any topical treatment on neck and/or chest within 6 months Pregnant and/or breastfeeding Infection, dermatitis or a rash in the treatment area Suffering from significant concurrent illness, such as Diabetes Mellitus or pertinent neurological disorders History of seizure disorders due to light, fibromyalgia, connective tissue disease, vitiligo, psoriasis, pigmentary disorders, keloid scarring, hypertrophic scarring or abnormal wound healing History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications Having a known anticoagulative condition or taking anticoagulation medications History of diseases stimulated by heat, unless treatment is conducted following a prophylactic regimen Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely) History of radiation to the head, neck and/or upper chest Undergoing systemic chemotherapy for the treatment of cancer Systemic use of isotretinoin (AccutaneÂ®) within 6 months Any use of gold therapy Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study Current smoker or history of smoking within 12 months of study Participation in a study of another device or drug within 6 months As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>poikiloderma of Civatte</keyword>
	<keyword>red dyschromia</keyword>
	<keyword>brown dyschromia</keyword>
	<keyword>sun damage</keyword>
	<keyword>neck</keyword>
	<keyword>chest</keyword>
	<keyword>dyschromia</keyword>
	<keyword>pigmentation disorders</keyword>
	<keyword>erythema</keyword>
	<keyword>photosensitivity disorders</keyword>
	<keyword>sun exposure</keyword>
	<keyword>telangiectasia</keyword>
	<keyword>hyperpigmentation</keyword>
	<keyword>hypopigmentation</keyword>
</DOC>